<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6272417</article-id><article-id pub-id-type="pmid">25871372</article-id><article-id pub-id-type="doi">10.3390/molecules20046533</article-id><article-id pub-id-type="publisher-id">molecules-20-06533</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Quercitrin, an Inhibitor of Sortase A, Interferes with the Adhesion of Staphylococcal aureus </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Bingrun</given-names></name><xref ref-type="aff" rid="af1-molecules-20-06533">1</xref><xref ref-type="author-notes" rid="fn1-molecules-20-06533">†</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Fuguang</given-names></name><xref ref-type="aff" rid="af1-molecules-20-06533">1</xref><xref ref-type="aff" rid="af2-molecules-20-06533">2</xref><xref ref-type="author-notes" rid="fn1-molecules-20-06533">†</xref></contrib><contrib contrib-type="author"><name><surname>Bi</surname><given-names>Chongwei</given-names></name><xref ref-type="aff" rid="af1-molecules-20-06533">1</xref><xref ref-type="author-notes" rid="fn1-molecules-20-06533">†</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Lin</given-names></name><xref ref-type="aff" rid="af3-molecules-20-06533">3</xref></contrib><contrib contrib-type="author"><name><surname>Zhong</surname><given-names>Xiaobo</given-names></name><xref ref-type="aff" rid="af1-molecules-20-06533">1</xref></contrib><contrib contrib-type="author"><name><surname>Cai</surname><given-names>Hongjun</given-names></name><xref ref-type="aff" rid="af1-molecules-20-06533">1</xref></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Xuming</given-names></name><xref ref-type="aff" rid="af3-molecules-20-06533">3</xref></contrib><contrib contrib-type="author"><name><surname>Niu</surname><given-names>Xiaodi</given-names></name><xref ref-type="aff" rid="af4-molecules-20-06533">4</xref><xref rid="c1-molecules-20-06533" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Dacheng</given-names></name><xref ref-type="aff" rid="af1-molecules-20-06533">1</xref><xref rid="c1-molecules-20-06533" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>McPhee</surname><given-names>Derek J.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-molecules-20-06533"><label>1</label>College of Animal Science, Jilin University, Changchun 130062, China; E-Mails: <email>lhglbr@outlook.com</email> (B.L.); <email>chenfuguang@caas.cn</email> (F.C.); <email>bicwei@163.com</email> (C.B.); <email>15043029208@163.com</email> (X.Z.); <email>chj6788571@163.com</email> (H.C.)</aff><aff id="af2-molecules-20-06533"><label>2</label>State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Science, Harbin 150001, China</aff><aff id="af3-molecules-20-06533"><label>3</label>Key Laboratory of Zoonosis Research, Ministry of Education, Institute of Zoonosis, College of Veterinary Medicine, Jilin University, Changchun 130062, China; E-Mails: <email>chj6788571@163.com</email> (L.W.); <email>dengxm@jlu.edu.cn</email> (X.D.)</aff><aff id="af4-molecules-20-06533"><label>4</label>Department of Food Quality and Safety, Jilin University, Changchun130062, China</aff><author-notes><fn id="fn1-molecules-20-06533"><label>†</label><p><text><SENT sid="1" pm="."><plain>These authors contributed equally to this work. </plain></SENT>
</text></p></fn><corresp id="c1-molecules-20-06533"><label>*</label> Authors to whom correspondence should be addressed; E-Mails: <email>niuxd@jlu.edu.cn</email> (X.N.); <email>wangdc@jlu.edu.cn</email> (D.W.); Tel./Fax: +86-431-87836161 (X.N. &amp; D.W.).</corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>4</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2015</year></pub-date><volume>20</volume><issue>4</issue><fpage>6533</fpage><lpage>6543</lpage><history><date date-type="received"><day>13</day><month>1</month><year>2015</year></date><date date-type="accepted"><day>08</day><month>4</month><year>2015</year></date></history><permissions><copyright-statement>© 2015 by the authors.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Sortase A (SrtA) is a cysteine transpeptidase of most Gram-positive bacteria that is responsible for the anchorage of many surface protein virulence factors to the cell wall layer. </plain></SENT>
<SENT sid="3" pm="."><plain>SrtA mutants are unable to display surface proteins and are defective in the establishment of infections without affecting microbial viability. </plain></SENT>
<SENT sid="4" pm="."><plain>In this study, we report that quercitrin (QEN), a natural compound that does not affect Staphylococcus aureus growth, can inhibit the catalytic activity of SrtA in fibrinogen (Fg) cell-clumping and immobilized fibronectin (Fn) adhesion assays. </plain></SENT>
<SENT sid="5" pm="."><plain>Molecular dynamics simulations and mutagenesis assays suggest that QEN binds to the binding sites of the SrtA G167A and V193A mutants. </plain></SENT>
<SENT sid="6" pm="."><plain>These findings indicate that QEN is a potential lead compound for the development of new anti-virulence agents against S. aureus infections. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>sortase A</kwd><kwd>quercitrin</kwd><kwd><italic>Staphylococcus aureus</italic></kwd><kwd>molecular modeling</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec><title><text><SENT sid="7" pm="."><plain>1. </plain></SENT>
<SENT sid="8" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="9" pm="."><plain>The Gram-positive pathogenic bacteria, Staphylococcus aureus (S. aureus), is the most commonly isolated human bacterial pathogen, which persistently and asymptomatically colonizes up to 20%–30% of humans and intermittently colonizes up to 50%–60% [1]. S. aureus colonizes human skin and mucosa, it also can cause many infectious diseases ranging from minor skin infections and abscesses to life-threatening diseases (such as necrotizing pneumonia, endocarditis, and septicemia) associated with high morbidity and mortality [2]. </plain></SENT>
<SENT sid="10" pm="."><plain>Methicillin-resistant S. aureus (MRSA) was first reported only two years after methicillin was applied for the treatment of penicillin-resistant bacteria. </plain></SENT>
<SENT sid="11" pm="."><plain>The reduced efficacy of vancomycin and linezolid against MRSA makes research into developing new treatment options a priority. </plain></SENT>
</text></p><p><text><SENT sid="12" pm="."><plain>The sortase enzymes, produced by most of Gram-positive bacteria, are a family of transpeptidases which can mediate the anchorage of surface protein virulence factors to the peptidoglycan cell wall layer via a cell C-terminal sorting signal reaction [3]. </plain></SENT>
<SENT sid="13" pm="."><plain>Numerous previous studies using knockout experiments have demonstrated that the sortase A (SrtA) isoform is constitutively expressed and cleaves the amide bond between the threonine and glycine of the LPXTG motif, which is found in many surface proteins that fulfill diverse functions during the infection process [4]. </plain></SENT>
<SENT sid="14" pm="."><plain>These surface proteins, used by Gram-positive pathogenic bacteria, play a critical role in the many processes of the establishment of an infection, including adherence, colonization, invasion, signaling and evasion of the host immune system [5]. </plain></SENT>
<SENT sid="15" pm="."><plain>Mazmanian et al. have evaluated the potential role of surface proteins in the pathogenesis of S. arueus infections using the mutant that lack the srtA gene [6]. </plain></SENT>
<SENT sid="16" pm="."><plain>Knockout mutations of the srtA gene in S. aureus interfere with the assembly of surface proteins into their envelope, preventing abscess formation in organ tissues or causing lethal bacteremia when inoculated into the bloodstream of mice [7,8]. Streptococcus gordonii SrtA mutants also failed to display the surface proteins, leading to a significant decrease of bacterial adhesion [9]. </plain></SENT>
<SENT sid="17" pm="."><plain>Therefore, SrtA inhibitors represent promising candidates for the development of therapeutics for the Gram-positive bacterial infections and may lead to new antibacterial drugs with novel mechanisms of action [10,11,12,13]. </plain></SENT>
</text></p><p><text><SENT sid="18" pm="."><plain>Currently, the increasing disease burden and the declining performance of traditional antimicrobial agents to combat bacteria-mediated disease make the development of alternative therapeutic strategies priority. </plain></SENT>
<SENT sid="19" pm="."><plain>Anti-virulence strategies have become a hot topic. </plain></SENT>
<SENT sid="20" pm="."><plain>We have screened anti-SrtA molecules from a number of detoxifying natural compounds by measuring their rate of inhibition of SrtA enzymatic activity. </plain></SENT>
<SENT sid="21" pm="."><plain>Quercitrin (QEN) was selected for to its strong inhibitory effect in our assays. </plain></SENT>
<SENT sid="22" pm="."><plain>In the present study, we observed that QEN, a natural bioflavonoid from Sabina pingii var. wilsonii that does not interfere with bacterial growth, could inhibit the catalytic activity of SrtA by binding directly to the active region of the SrtA, indicating that this agent may be a useful lead compound for developing novel antiinfective drugs. </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS,DISCUSS"><sec><title><text><SENT sid="23" pm="."><plain>2. </plain></SENT>
<SENT sid="24" pm="."><plain>Results and Discussion </plain></SENT>
</text></title><sec><title><text><SENT sid="25" pm="."><plain>2.1. </plain></SENT>
<SENT sid="26" pm="."><plain>QEN Blocks the Thioesterification Process of Sortase A Catalysis </plain></SENT>
</text></title><p><text><SENT sid="27" pm="."><plain>Among the 27 compounds screened (Table 1), we found that QEN, a natural bioflavonoid from Sabina pingii var. wilsonii, was able to remarkably inhibit the catalytic activity of purified SrtA via sortase activity inhibition assay. </plain></SENT>
<SENT sid="28" pm="."><plain>In our experimental system, the concentration of QEN required for 50% inhibition (half maximal inhibitory concentration, IC50) was 32.18 ± 5.36 μg/mL. </plain></SENT>
<SENT sid="29" pm="."><plain>Additionally, the minimum inhibitory concentrations (MICs) of QEN against the tested S. aureus strains (S. aureus Newman D2C and the srtA mutant) were both greater than 1024 μg/mL. </plain></SENT>
<SENT sid="30" pm="."><plain>The growth curve of Newman D2C treated with or without QEN was also monitored and showed that bacterial growth was mostly unaffected by QEN, even at a concentration of 256 μg/mL. </plain></SENT>
<SENT sid="31" pm="."><plain>The growth rate of the Newman ∆SrtA strain was similar to that of the wild-type Newman D2C strain. </plain></SENT>
<SENT sid="32" pm="."><plain>Taken together, our results indicate that QEN is capable of effectively inhibiting the catalytic activity of SrtA, but has little effect on bacterial growth (Figure 1B,C). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="molecules-20-06533-f001" position="float"><label>Figure 1</label><caption><p><text><SENT sid="33" pm="."><plain>QEN blocks the thioesterification process of SrtA catalysis, but does not inhibit bacterial physiology. </plain></SENT>
<SENT sid="34" pm="."><plain>(A) The chemical structure of QEN. </plain></SENT>
<SENT sid="35" pm="."><plain>(B) The growth curve of S. aureus treated with or without QEN. S. aureus were cultured in BHI without QEN or with 256 μg/mL QEN, and the absorbency readings of the samples were taken at OD600 at the indicated time point. </plain></SENT>
<SENT sid="36" pm="."><plain>(C) QEN blocks the catalytic activity of SrtA. </plain></SENT>
<SENT sid="37" pm="."><plain>The fluorescent peptide was incubated with purified SrtA treated with the indicated concentrations of QEN at 37 °C for 30 min, and the fluorescence was measured 1 h after adding the substrate-modified peptide. </plain></SENT>
</text></p></caption><graphic xlink:href="molecules-20-06533-g001"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="molecules-20-06533-t001" position="float"><object-id pub-id-type="pii">molecules-20-06533-t001_Table 1</object-id><label>Table 1</label><caption><p><text><SENT sid="38" pm="."><plain>Compounds screened. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3" align="center" valign="middle" rowspan="1"><text><SENT sid="39" pm="."><plain>Compounds </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="40" pm="."><plain>Quercitrin </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="41" pm="."><plain>Vitexin </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="42" pm="."><plain>Isoliquiritin </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="43" pm="."><plain>Liquiritigenin </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="44" pm="."><plain>Tetrandrine </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="45" pm="."><plain>Honokiol </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="46" pm="."><plain>Cyrtopterinetin </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="47" pm="."><plain>Fisetin </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="48" pm="."><plain>Eleutheroside A </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="49" pm="."><plain>Chrysin </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="50" pm="."><plain>Daidzin </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="51" pm="."><plain>Quinine </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="52" pm="."><plain>Formononetin </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="53" pm="."><plain>Emodin </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="54" pm="."><plain>Sodium houttufonate </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="55" pm="."><plain>Tectorigenin </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="56" pm="."><plain>Psoralen </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="57" pm="."><plain>Dryocrassin </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="58" pm="."><plain>Viola yedoensis extract </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="59" pm="."><plain>Andrographolide </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="60" pm="."><plain>Wogonoside </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="61" pm="."><plain>Prunella vulgaris leaf extract </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="62" pm="."><plain>Artemisinin </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="63" pm="."><plain>Radix platycodi extract </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="64" pm="."><plain>Forsythin </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="65" pm="."><plain>Kaempferol </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="66" pm="."><plain>Berberine </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag></sec><sec><title><text><SENT sid="67" pm="."><plain>2.2. </plain></SENT>
<SENT sid="68" pm="."><plain>QEN Inhibits Adherence of S. aureus to Cell-Matrix Proteins </plain></SENT>
</text></title><p><text><SENT sid="69" pm="."><plain>An active sortase enzyme is indispensable for the adherence of S. aureus to host cell matrices and establishment of an infection. ∆srtA mutant strains cannot bind to cell-matrix proteins (such as fibrinogen and fibronectin) in vitro [8]. </plain></SENT>
<SENT sid="70" pm="."><plain>Therefore, the ability of QEN to inhibit the adherence of S. aureus to fibrinogen or fibronectin was tested using an assay of cell adhesion to fibrinogen-coated or fibronectin-coated plates by measuring the absorbance following staining with crystal violet. </plain></SENT>
<SENT sid="71" pm="."><plain>As expected, both the fibrinogen and fibronectin binding activities of the ∆srtA mutant strain were almost completely lost. </plain></SENT>
<SENT sid="72" pm="."><plain>The treatment of Newman D2C with QEN led to a significant reduce for the attachment of bacteria to fibrinogen-coated or fibronectin-coated surfaces. </plain></SENT>
<SENT sid="73" pm="."><plain>Importantly, when treated with 64 μg/mL QEN, the absorbance values (OD at 570 nm) were only 51.90% and 49.60% in the fibrinogen binding assay and the fibronectin binding assay (Figure 2A,B), respectively. </plain></SENT>
<SENT sid="74" pm="."><plain>Taken together, our results suggest that QEN inhibits SrtA activity in vitro and in turn reduces fibrinogen-binding protein and fibronectin-binding protein surface display. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="molecules-20-06533-f002" position="float"><label>Figure 2</label><caption><p><text><SENT sid="75" pm="."><plain>QEN inhibits the adherence of S. aureus to fibrinogen and fibronectin. </plain></SENT>
<SENT sid="76" pm="."><plain>Bacteria treated with the indicated concentrations of QEN were incubated in fibrinogen- or fibronectin-coated 96-well plates for 2 h at 37 °C, and the adhesion of S. aureus to fibrinogen (A) and fibronectin (B) was measured. *p &lt; 0.05 and **p &lt; 0.01. </plain></SENT>
</text></p></caption><graphic xlink:href="molecules-20-06533-g002"/></fig></SecTag></sec><sec><title><text><SENT sid="77" pm="."><plain>2.3. </plain></SENT>
<SENT sid="78" pm="."><plain>Determination of the Binding Mode of SrtA with QEN </plain></SENT>
</text></title><p><text><SENT sid="79" pm="."><plain>Results from our functional analyses strongly suggested direct binding of SrtA by QEN; we next explored the mechanism of action of this agent by studying its interactions with the enzyme using molecular modeling. </plain></SENT>
<SENT sid="80" pm="."><plain>The initial structure of SrtA was obtained from the NMR structure (PDB code: 1IJA) [14]. </plain></SENT>
<SENT sid="81" pm="."><plain>The preferential binding mode of SrtA with QEN was determined by 20-ns molecular dynamics simulations based on the docking results. </plain></SENT>
<SENT sid="82" pm="."><plain>The root-mean-square deviation (RMSD) values of the protein were calculated and are plotted in Figure 3A. </plain></SENT>
<SENT sid="83" pm="."><plain>As shown in Figure 3A the protein structures of all the systems were stabilized during the simulations. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="molecules-20-06533-f003" position="float"><label>Figure 3</label><caption><p><text><SENT sid="84" pm="."><plain>Structures of the screening compounds. </plain></SENT>
<SENT sid="85" pm="."><plain>(A) The root-mean-square deviations (RMSD) of all the atoms of SrtA-QEN complexes with respect to their initial structures as a function of time. </plain></SENT>
<SENT sid="86" pm="."><plain>(B) The predicted binding mode of QEN in the SrtA binding pocket obtained from the MD simulation. </plain></SENT>
<SENT sid="87" pm="."><plain>(C) RMSFs of residues of the whole protein in the SrtA-QEN complex and free SrtA during the last 10-ns simulation. </plain></SENT>
<SENT sid="88" pm="."><plain>(D) Decomposition of the binding energy on a per-residue basis in the SrtA-QEN complex. </plain></SENT>
</text></p></caption><graphic xlink:href="molecules-20-06533-g003"/></fig></SecTag><p><text><SENT sid="89" pm="."><plain>In the simulation, QEN can bind to SrtA via hydrogen bonding and hydrophobic interactions as a ligand. </plain></SENT>
<SENT sid="90" pm="."><plain>Over the time course of the simulation, QEN localizes to the active region, which is reported to participate in reactivity and is important for SrtA function [15]. </plain></SENT>
<SENT sid="91" pm="."><plain>The structure of SrtA-QEN is illustrated in Figure 3B, and the electrostatic potentials of the protein were mapped using the APBS software. </plain></SENT>
<SENT sid="92" pm="."><plain>Specifically, the structure of SrtA-QEN (Figure 3B) showed that the 4H-chromen-4-one moiety of QEN formed both a strong interaction with the side-chain amino group of Ala104 and the side-chain carbonyl group of Ser106. </plain></SENT>
<SENT sid="93" pm="."><plain>Moreover, the side chains of Val193, Val166, Gly167, and Val168 can form van der Waals interactions with QEN (Figure 3A </plain></SENT>
</text></p><p><text><SENT sid="94" pm="."><plain>The root mean square fluctuations (RMSF) of the residues of the whole protein in the SrtA-QEN complex and free protein were calculated, as shown in Figure 3C which clearly depicts the different flexibilities in the binding site of SrtA in the presence and absence of QEN. </plain></SENT>
<SENT sid="95" pm="."><plain>All of the residues in the SrtA binding site that bind to QEN show a RMSFs of less than 4.00 Å, with a smaller degree of flexibility, compared with those of free SrtA, which is indicated that these residues seem to be more rigid due to the binding to QEN. </plain></SENT>
<SENT sid="96" pm="."><plain>These results indicate that the stabilization at the binding sites of SrtA in this complex was mostly due to residues Ala104, Val193, Val166, Gly167, and Val168, as shown in Figure 3B. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="97" pm="."><plain>2.4. </plain></SENT>
<SENT sid="98" pm="."><plain>Identification of the Binding Site in the SrtA-QEN Complex </plain></SENT>
</text></title><p><text><SENT sid="99" pm="."><plain>The energy contributions from the selected residues are summarized in Figure 3D. </plain></SENT>
<SENT sid="100" pm="."><plain>Ala104 had an appreciable electrostatic (ΔEele) contribution, with a ΔEele of ≤−5.0 kcal/mol (Figure 3D). </plain></SENT>
<SENT sid="101" pm="."><plain>In fact, Ala104 is close to the 4H-chromen-4-one moiety of QEN, and electrostatic interactions exist, leading to one strong electrostatic interaction between SrtA and QEN. </plain></SENT>
<SENT sid="102" pm="."><plain>In addition, the Val166, Gly167 and Val168 residues, with ΔEvdw’s of ≤ −2.0 kcal/mol, have strong Van der Waals interactions with QEN due to the close proximity between these residues and QEN. </plain></SENT>
<SENT sid="103" pm="."><plain>Moreover, the Val193 residue, with a ΔEvdw of ≤ −3.0 kcal/mol, also has a strong Van der Waals interaction with QEN. </plain></SENT>
<SENT sid="104" pm="."><plain>Except for the Val168 and Val193 residues, the majority of the binding free energy originated from electrostatic interactions. </plain></SENT>
<SENT sid="105" pm="."><plain>The total binding free energy for the SrtA-QEN complex and its detailed energy contributions, are summarized in Table 2. </plain></SENT>
<SENT sid="106" pm="."><plain>With the summation of the solute entropy term (~5.9 kcal/mol), an estimated ΔGbind of −11.7 kcal/mol was calculated for QEN, suggesting that QEN can strongly bind to the activity cavity of SrtA. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="molecules-20-06533-t002" position="float"><object-id pub-id-type="pii">molecules-20-06533-t002_Table 2</object-id><label>Table 2</label><caption><p><text><SENT sid="107" pm="."><plain>The calculated energy components, binding free energy (kcal/mol), binding constants and number of binding sites of the WT-QEN, G167A-QEN and V193A-QEN systems based on the fluorescence spectroscopy quenching method. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1"><text></text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="108" pm="."><plain>TΔS (kcal/mol) </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="109" pm="."><plain>ΔGbind (kcal/mol) </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain>Binding Constants KA (1 × 105) L·mol−1 </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain>n </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>WT-QEN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>5.9 ± 1.8 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="114" pm="."><plain>−11.7 ± 1.4 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain>6.9 ± 1.3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>0.9991 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>G167A-QEN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain>6.2 ± 1.6 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>−5.6 ± 1.9 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>3.7 ± 0.7 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>1.0044 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>V193A-QEN </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>6.1 ± 1.5 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>−7.4 ± 1.3 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>4.2 ± 1.1 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>0.9996 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><p><text><SENT sid="127" pm="."><plain>To examine the accuracy of the binding site in the complex, the mutant complexes G167A-QEN and V193A-QEN were used as the preliminary structures for MD simulations. </plain></SENT>
<SENT sid="128" pm="."><plain>The MM-GBSA calculation predicted that G167A and V193A bind more weakly to QEN than the WT-SrtA (−5.6 kcal/mol for G167A and −7.4 kcal/mol for V193A), as shown in Table 2. </plain></SENT>
<SENT sid="129" pm="."><plain>The calculations for G167A and V193A showed that these mutations resulted in a decrease of approximately 7 kcal/mol of binding energy compared with the WT-SrtA. </plain></SENT>
<SENT sid="130" pm="."><plain>According to the experimental results, the binding constants or KAs of the interaction between QEN and SrtA decreased in the following order: WT &gt; V193A &gt; G167A. </plain></SENT>
<SENT sid="131" pm="."><plain>This result indicates that WT-SrtA has the strongest ability to bind to QEN and G167A has the weakest ability, as shown in Table 2. </plain></SENT>
<SENT sid="132" pm="."><plain>The calculated binding free energies were consistent with the experimental data. </plain></SENT>
<SENT sid="133" pm="."><plain>Therefore, MD simulations exactly generated a reliable SrtA-QEN complex. </plain></SENT>
</text></p><p><text><SENT sid="134" pm="."><plain>The Ala104, Val193, Val166, Gly167, and Val168 residues have a key role in the binding of QEN to SrtA, which is identical with previous reports [15,16]. </plain></SENT>
<SENT sid="135" pm="."><plain>It is plausible that due to the binding of QEN with the activity region (the Ala104, Val193, Val166, Gly167, and Val168 residues), the biological activity of SrtA was inhibited. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="136" pm="."><plain>2.5. </plain></SENT>
<SENT sid="137" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="138" pm="."><plain>Compared with traditional strategies that are aimed at killing bacteria or preventing their growth, this anti-virulence approach diminishes the rate of development of bacterial resistance. </plain></SENT>
<SENT sid="139" pm="."><plain>Furthermore, the specific effect of anti-virulence drugs could aid the host immune system in preventing bacterial colonization or clearing established infections [5,17,18,19]. </plain></SENT>
<SENT sid="140" pm="."><plain>In this study, we demonstrated that QEN, a natural bioflavonoid from Sabina pingii var. wilsonii without any effect on bacterial growth, was able to significantly inhibit the catalytic activity of SrtA, a critical virulence factor that mediates the anchorage of surface protein virulence factors to the peptidoglycan cell wall layer of Gram-positive pathogens. </plain></SENT>
<SENT sid="141" pm="."><plain>Importantly, the binding activity of S. aureus to fibrinogen or fibronectin was remarkably reduced upon treatment with QEN compared with untreated controls, suggesting that QEN is an effective inhibitor of SrtA activity in vivo. </plain></SENT>
<SENT sid="142" pm="."><plain>In summary, the above findings indicate that QEN can inhibit the catalytic activity of SrtA in vitro without anti-bacterial activity and may be used as a promising lead compound for the development of an anti-virulence agent against S. aureus infections specially targeting SrtA. </plain></SENT>
<SENT sid="143" pm="."><plain>Additionally, the data presented in this work further provides the basis for analysis of the structure-activity relationship and in vitro activity of sortase A inhibitors. </plain></SENT>
</text></p></sec></sec></SecTag><sec><title><text><SENT sid="144" pm="."><plain>3. </plain></SENT>
<SENT sid="145" pm="."><plain>Experimental Section </plain></SENT>
</text></title><sec><title><text><SENT sid="146" pm="."><plain>3.1. </plain></SENT>
<SENT sid="147" pm="."><plain>Bacterial Strains, Plasmids and Reagents </plain></SENT>
</text></title><p><text><SENT sid="148" pm="."><plain>The bacterial strains and plasmids used in this work are presented in Table 3. S. aureus Newman D2C and its srtA mutant were cultured in brain-heart infusion (BHI) media at 37 °C. </plain></SENT>
<SENT sid="149" pm="."><plain>The fluorescent peptide Dabcyl-QALPETGEE-Edans was synthesized by GL Biochem (Shanghai, China). </plain></SENT>
<SENT sid="150" pm="."><plain>Compound quercitrin (QEN) was purchased from the National Institutes for Food and Drug Control of Chain and dissolved in DMSO (Sigma-Aldrich, St. Louis, MO, USA). </plain></SENT>
<SENT sid="151" pm="."><plain>Other reagents were obtained from Sigma-Aldrich unless otherwise noted. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="molecules-20-06533-t003" position="float"><object-id pub-id-type="pii">molecules-20-06533-t003_Table 3</object-id><label>Table 3</label><caption><p><text><SENT sid="152" pm="."><plain>Strain and plasmid list. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>Strain or Plasmid </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>Relevant Genotype </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>Source or Reference </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>Strains </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text></text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text></text></td></tr><tr style="border-top:solid thin"><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>S. aureus </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text></text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text></text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain>Newman D2C </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>Wild-type SrtA positive; nonhemolytic; coagulase Negative </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>ATCC25904 </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>ΔSrtA </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>srtA::Emr; isogenic mutant of Newman D2C </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text></text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>E. coli </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text></text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text></text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>BL21 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>Expression strain, F− ompT hsdS(rB− mB−) gal dcm (DE3) </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>Invitrogen </plain></SENT>
</text></td></tr><tr style="border-top:solid thin"><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>Plasmids </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text></text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text></text></th></tr><tr style="border-top:solid thin"><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>pGEX-6P-1 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>Expression vector </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>Amersham </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>pGSrtAΔN59 </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>pGEX-6P-1 with srtA gene </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>This study </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>G167A </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>pGSrtAΔN59 derivative, for the substitution of Gly167 with alanine </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>This study </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>V193A </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>pGSrtAΔN59 derivative, for the substitution of Val192 with alanine </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>This study </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag></sec><sec><title><text><SENT sid="180" pm="."><plain>3.2. </plain></SENT>
<SENT sid="181" pm="."><plain>Preparation of Recombinant SrtAΔN59 and Its Mutant </plain></SENT>
</text></title><p><text><SENT sid="182" pm="."><plain>The DNA fragment encoding SrtAΔN59 (residues 60-206) was PCR-amplified from the genomic DNA of S. aureus Newman D2C using the primers PsrtA59F and PsrtA59R and cloned into the pGEX-6P-1 vector to generate the pGSrtAΔN59 construct. </plain></SENT>
<SENT sid="183" pm="."><plain>Site-directed mutagenesis was performed on pGSrtAΔN59 to produce the mutations G167A and V193A using the QuikChange Site-Directed Mutagenesis Kit according to the manufacturer’s protocol (Stratagene, La Jolla, CA, USA). </plain></SENT>
<SENT sid="184" pm="."><plain>The pGSrtAΔN59 plasmid and the mutant constructs were transformed into BL21 Escherichia coli (Invitrogen, Carlsbad, CA, USA). </plain></SENT>
<SENT sid="185" pm="."><plain>The transformed bacteria were then grown in 1 L of LB broth containing ampicillin (100 μg/mL) at 37 °C until the OD600 reached 0.6–0.8, and the expression of interest protein was induced with 1 mM isopropyl β-d-1-thiogalactopyranoside (IPTG, Invitrogen). </plain></SENT>
<SENT sid="186" pm="."><plain>The cells were harvested (5000× g for 5 min) after overnight culturing at 23 °C, and the recombinant protein was purified on a GST affinity column (2 mL glutathione Sepharose 4B) (GE Amersham Biosciences, Piscataway, NJ, USA). </plain></SENT>
<SENT sid="187" pm="."><plain>All expression vectors were confirmed via DNA sequencing. </plain></SENT>
<SENT sid="188" pm="."><plain>The complementary forward and reverse primer pairs used in SrtAΔN59 variant construction are listed in Table 4. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="molecules-20-06533-t004" position="float"><object-id pub-id-type="pii">molecules-20-06533-t004_Table 4</object-id><label>Table 4</label><caption><p><text><SENT sid="189" pm="."><plain>Oligonucleotide primers used in this study. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>Primer Name </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>Oligonucleotide (5–3) ᵅ </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>PsrtA59F </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>GCGGGATCCCCGGAATTCCAAGCTAAACCTCAAATTCC </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>PsrtA59R </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>CCGCTCGAGTTATTTGACTTCTGTAGCTACAA </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>G167A–F </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="197" pm="."><plain>AGCCAACAGATGTAGCAGTTCTAGAT </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="198" pm="."><plain>G167A–R </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="199" pm="."><plain>AGAACGCTACATCTGTTGGCTTAACATCTC </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="200" pm="."><plain>V193A–F </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="201" pm="."><plain>TGAAAAGACAGGCGCTTGGGAAAAAC </plain></SENT>
</text></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="202" pm="."><plain>V193A–R </plain></SENT>
</text></td><td align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="203" pm="."><plain>TTCCCAGCGCCTGTCTTTTCATTGTAATCAT </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="204" pm="."><plain>a Restriction endonuclease recognition sites or mutated codons are underlined. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec><title><text><SENT sid="205" pm="."><plain>3.3. </plain></SENT>
<SENT sid="206" pm="."><plain>Sortase Activity Inhibition Assay </plain></SENT>
</text></title><p><text><SENT sid="207" pm="."><plain>The inhibitory activities of QEN against Sortase were determined using a fluorescence resonance energy transfer (FRET) assay, which was performed in 300 μL reactions containing 50 mM Tris-HCl; 5 mM CaCl2; 150 mM NaCl, pH7.5; 4 μM of recombinant SrtAΔN59; and 10 μM of fluorescent peptide (Dabcyl-QALPETGEE-Edans). </plain></SENT>
<SENT sid="208" pm="."><plain>QEN was added to the 96-well plate to reach the indicated concentrations, and they were then incubated at 37 °C for 30 min before adding the substrate-modified peptide and allowing the reaction to proceed for 1 h at 37 °C. </plain></SENT>
<SENT sid="209" pm="."><plain>The fluorescence of each sample was measured with the emission and excitation wavelengths set at 495 and 350 nm, respectively. </plain></SENT>
<SENT sid="210" pm="."><plain>Each concentration was repeated three times independently in this experiment. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="211" pm="."><plain>3.4. </plain></SENT>
<SENT sid="212" pm="."><plain>Determination of Minimum Inhibitory Concentration (MIC) and Growth Curves </plain></SENT>
</text></title><p><text><SENT sid="213" pm="."><plain>The MICs of QEN against S. aureus was determined as previously described [20]. </plain></SENT>
<SENT sid="214" pm="."><plain>To plot growth curves, 1 mL of an overnight S. aureus bacteria culture was added to 50 mL of fresh BHI broth and incubated at 37 °C with or without the tested compound for 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 18, and 24 h. </plain></SENT>
<SENT sid="215" pm="."><plain>Absorbency readings were taken at OD600. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="216" pm="."><plain>3.5. </plain></SENT>
<SENT sid="217" pm="."><plain>Fibrinogen-Binding and Fibronectin-Binding Assays </plain></SENT>
</text></title><p><text><SENT sid="218" pm="."><plain>The S. aureus wild-type strain was cultured overnight, diluted 1:100 in BHI broth, and incubated with the indicated concentrations of QEN in a shaking incubator at 37 °C to an initial OD600 of 0.05. </plain></SENT>
<SENT sid="219" pm="."><plain>The Newman ∆SrtA strain was grown under the same conditions and used as a positive control. </plain></SENT>
<SENT sid="220" pm="."><plain>All samples were cultivated for 2 h on a rotary shaker at 37 °C, and the cells were then pelleted by centrifugation (5000× g for 5 min), washed twice, and resuspended in PBS to an OD600 of 1.0 prior to their use in experiments. </plain></SENT>
<SENT sid="221" pm="."><plain>The cell suspensions were added to a polystyrene Costar 96-well plate, which had been coated overnight at 4 °C with 100 μL of a 20 μg/mL bovine fibrinogen (Fg) or a 20 μg/mL human plasma fibronectin (Fn) solution. </plain></SENT>
<SENT sid="222" pm="."><plain>After a 2 h incubation at 37 °C, the suspension was removed and the plate was stained with crystal violet for 15 min and the absorbances of the plated samples were subsequently read at 570 nm with a microplate reader. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="223" pm="."><plain>3.6. </plain></SENT>
<SENT sid="224" pm="."><plain>Computational Chemistry </plain></SENT>
</text></title><p><text><SENT sid="225" pm="."><plain>The relevant molecular modeling methods of protein and ligands are performed based on our previously reported work [21]. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="226" pm="."><plain>3.7. </plain></SENT>
<SENT sid="227" pm="."><plain>Binding Affinity Determination of QEN with WT-SrtAΔN59, G167A and V193A </plain></SENT>
</text></title><p><text><SENT sid="228" pm="."><plain>The binding constants (KAs) of QEN to the binding sites on WT-SrtAΔN59 (WT-SrtA), the G167A mutant, and the V193A mutants were measured using the fluorescence-quenching method, as presented in the previous report [21]. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="229" pm="."><plain>3.8. </plain></SENT>
<SENT sid="230" pm="."><plain>Statistical Analysis </plain></SENT>
</text></title><p><text><SENT sid="231" pm="."><plain>The statistical significances of all assays were calculated using the 2-tailed Student’s t-test. </plain></SENT>
<SENT sid="232" pm="."><plain>Differences were considered statistically significant when p &lt; 0.05. </plain></SENT>
</text></p></sec></sec></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="233" pm="."><plain>This work was supported by the Natural Basic Research Program of China (grant 2013CB127205), National Nature Science Foundation of China (No. 31130053) and the 863 Program (No. 2012AA020303 and No. 2011AA10A214). </plain></SENT>
<SENT sid="234" pm="."><plain>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. </plain></SENT>
</text></text4fund></p></ack></SecTag><fn-group><fn><p><text><SENT sid="235" pm="."><plain>Samples Availability: Samples of the compounds screened in this study are available from the authors. </plain></SENT>
</text></p></fn></fn-group><notes><title>Author Contributions</title><p>D.W., X.D. and B.L. designed the research and wrote the manuscript; B.L., X.N., F.C., L.W., C.B., X.Z., H.C. performed the experimental work; X.N. analyzed the data. All authors discussed, edited and approved the final version.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><SecTag type="REF"><ref-list><title>References</title><ref id="B1-molecules-20-06533"><text><SENT sid="236" pm="."><plain>1. WertheimH.F.MellesD.C.VosM.C.van LeeuwenW.van BelkumA.VerbrughH.A.NouwenJ.L. The role of nasal carriage in Staphylococcus aureus infections Lancet Infect. </plain></SENT>
<SENT sid="237" pm="."><plain>Dis. 2005 5 751 762 10.1016/S1473-3099(05)70295-4 <?supplied-pmid 16310147?>16310147 </plain></SENT>
</text></ref><ref id="B2-molecules-20-06533"><text><SENT sid="238" pm="."><plain>2. LowyF.D. Staphylococcus aureus infections N. Engl. </plain></SENT>
<SENT sid="240" pm="."><plain>J. </plain></SENT>
<SENT sid="241" pm="."><plain>Med. 1998 339 520 532 10.1056/NEJM199808203390806 <?supplied-pmid 9709046?>9709046 </plain></SENT>
</text></ref><ref id="B3-molecules-20-06533"><text><SENT sid="242" pm="."><plain>3. OhK.B.OhM.N.KimJ.G.ShinD.S.ShinJ. Inhibition of sortase-mediated Staphylococcus aureus adhesion to fibronectin via fibronectin-binding protein by sortase inhibitors Appl. </plain></SENT>
<SENT sid="243" pm="."><plain>Microbiol. </plain></SENT>
<SENT sid="244" pm="."><plain>Biotechnol. 2006 70 102 106 10.1007/s00253-005-0040-8 <?supplied-pmid 16010573?>16010573 </plain></SENT>
</text></ref><ref id="B4-molecules-20-06533"><text><SENT sid="245" pm="."><plain>4. IlangovanU.Ton-ThatH.IwaharaJ.SchneewindO.ClubbR.T. Structure of sortase, the transpeptidase that anchors proteins to the cell wall of Staphylococcus aureus Proc. </plain></SENT>
<SENT sid="246" pm="."><plain>Natl. </plain></SENT>
<SENT sid="247" pm="."><plain>Acad. </plain></SENT>
<SENT sid="248" pm="."><plain>Sci. </plain></SENT>
<SENT sid="249" pm="."><plain>USA 2001 98 6056 6061 10.1073/pnas.101064198 <?supplied-pmid 11371637?>11371637 </plain></SENT>
</text></ref><ref id="B5-molecules-20-06533"><text><SENT sid="250" pm="."><plain>5. CossartP.JonquieresR. Sortase, a universal target for therapeutic agents against gram-positive bacteria? Proc. </plain></SENT>
<SENT sid="251" pm="."><plain>Natl. </plain></SENT>
<SENT sid="252" pm="."><plain>Acad. </plain></SENT>
<SENT sid="253" pm="."><plain>Sci. </plain></SENT>
<SENT sid="254" pm="."><plain>USA 2000 97 5013 5015 10.1073/pnas.97.10.5013 <?supplied-pmid 10805759?>10805759 </plain></SENT>
</text></ref><ref id="B6-molecules-20-06533"><text><SENT sid="255" pm="."><plain>6. JonssonI.M.MazmanianS.K.SchneewindO.VerdrenghM.BremellT.TarkowskiA. On the role of Staphylococcus aureus sortase and sortase-catalyzed surface protein anchoring in murine septic arthritis J. Infect. </plain></SENT>
<SENT sid="257" pm="."><plain>Dis. 2002 185 1417 1424 10.1086/340503 <?supplied-pmid 11992276?>11992276 </plain></SENT>
</text></ref><ref id="B7-molecules-20-06533"><text><SENT sid="258" pm="."><plain>7. ChengA.G.KimH.K.BurtsM.L.KrauszT.SchneewindO.MissiakasD.M. Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues FASEB J. 2009 23 3393 3404 10.1096/fj.09-135467 <?supplied-pmid 19525403?>19525403 </plain></SENT>
</text></ref><ref id="B8-molecules-20-06533"><text><SENT sid="259" pm="."><plain>8. McAdowM.KimH.K.DedentA.C.HendrickxA.P.SchneewindO.MissiakasD.M. Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood PLoS Pathogens 2011 7 e1002307 10.1371/journal.ppat.1002307 <?supplied-pmid 22028651?>22028651 </plain></SENT>
</text></ref><ref id="B9-molecules-20-06533"><text><SENT sid="260" pm="."><plain>9. BolkenT.C.FrankeC.A.ZellerG.O.HrubyD.E. Identification of an intragenic integration site for foreign gene expression in recombinant Streptococcus gordonii strains Appl. </plain></SENT>
<SENT sid="261" pm="."><plain>Microbiol. </plain></SENT>
<SENT sid="262" pm="."><plain>Biotechnol. 2001 55 192 197 10.1007/s002530000519 <?supplied-pmid 11330713?>11330713 </plain></SENT>
</text></ref><ref id="B10-molecules-20-06533"><text><SENT sid="263" pm="."><plain>10. ChanA.H.WereszczynskiJ.AmerB.R.YiS.W.JungM.E.McCammonJ.A.ClubbR.T. Discovery of Staphylococcus aureus sortase A inhibitors using virtual screening and the relaxed complex scheme Chem. </plain></SENT>
<SENT sid="264" pm="."><plain>Biol. </plain></SENT>
<SENT sid="265" pm="."><plain>Drug Des. 2013 82 418 428 10.1111/cbdd.12167 <?supplied-pmid 23701677?>23701677 </plain></SENT>
</text></ref><ref id="B11-molecules-20-06533"><text><SENT sid="266" pm="."><plain>11. ZhulenkovsD.RudevicaZ.JaudzemsK.TurksM.LeonchiksA. Discovery and structure-activity relationship studies of irreversible benzisothiazolinone-based inhibitors against Staphylococcus aureus sortase A transpeptidase Bioorganic Med. </plain></SENT>
<SENT sid="267" pm="."><plain>Chem. 2014 22 5988 6003 10.1016/j.bmc.2014.09.011  </plain></SENT>
</text></ref><ref id="B12-molecules-20-06533"><text><SENT sid="268" pm="."><plain>12. KahlonA.K.NegiA.S.KumariR.SrivastavaK.K.KumarS.DarokarM.P.SharmaA. Identification of 1-chloro-2-formyl indenes and tetralenes as novel antistaphylococcal agents exhibiting sortase A inhibition Appl. </plain></SENT>
<SENT sid="269" pm="."><plain>Microbiol. </plain></SENT>
<SENT sid="270" pm="."><plain>Biotechnol. 2014 98 2041 2051 10.1007/s00253-013-5036-1 <?supplied-pmid 23817664?>23817664 </plain></SENT>
</text></ref><ref id="B13-molecules-20-06533"><text><SENT sid="271" pm="."><plain>13. UddinR.LodhiM.U.Ul-HaqZ. Combined pharmacophore and 3D-QSAR study on a series of Staphylococcus aureus Sortase A inhibitors Chem. </plain></SENT>
<SENT sid="272" pm="."><plain>Biol. </plain></SENT>
<SENT sid="273" pm="."><plain>Drug Des. 2012 80 300 314 10.1111/j.1747-0285.2012.01403.x <?supplied-pmid 22553957?>22553957 </plain></SENT>
</text></ref><ref id="B14-molecules-20-06533"><text><SENT sid="274" pm="."><plain>14. SureeN.LiewC.K.VillarealV.A.ThieuW.FadeevE.A.ClemensJ.J.JungM.E.ClubbR.T. The structure of the Staphylococcus aureus sortase-substrate complex reveals how the universally conserved LPXTG sorting signal is recognized J. Biol. </plain></SENT>
<SENT sid="276" pm="."><plain>Chem. 2009 284 24465 24477 10.1074/jbc.M109.022624 <?supplied-pmid 19592495?>19592495 </plain></SENT>
</text></ref><ref id="B15-molecules-20-06533"><text><SENT sid="277" pm="."><plain>15. Ton-ThatH.MazmanianS.K.FaullK.F.SchneewindO. Anchoring of surface proteins to the cell wall of Staphylococcus aureus—Sortase catalyzed in vitro transpeptidation reaction using LPXTG peptide and NH2-Gly(3) substrates J. Biol. </plain></SENT>
<SENT sid="279" pm="."><plain>Chem. 2000 275 9876 9881 10.1074/jbc.275.13.9876 <?supplied-pmid 10734144?>10734144 </plain></SENT>
</text></ref><ref id="B16-molecules-20-06533"><text><SENT sid="280" pm="."><plain>16. Ton-ThatH.LiuG.MazmanianS.K.FaullK.F.SchneewindO. Purification and characterization of sortase, the transpeptidase that cleaves surface proteins of Staphylococcus aureus at the LPXTG motif Proc. </plain></SENT>
<SENT sid="281" pm="."><plain>Natl. </plain></SENT>
<SENT sid="282" pm="."><plain>Acad. </plain></SENT>
<SENT sid="283" pm="."><plain>Sci. </plain></SENT>
<SENT sid="284" pm="."><plain>USA 1999 96 12424 12429 10.1073/pnas.96.22.12424 <?supplied-pmid 10535938?>10535938 </plain></SENT>
</text></ref><ref id="B17-molecules-20-06533"><text><SENT sid="285" pm="."><plain>17. EscaichS. Antivirulence as a new antibacterial approach for chemotherapy Curr. </plain></SENT>
<SENT sid="286" pm="."><plain>Opin. </plain></SENT>
<SENT sid="287" pm="."><plain>Chem. </plain></SENT>
<SENT sid="288" pm="."><plain>Biol. 2008 12 400 408 10.1016/j.cbpa.2008.06.022 <?supplied-pmid 18639647?>18639647 </plain></SENT>
</text></ref><ref id="B18-molecules-20-06533"><text><SENT sid="289" pm="."><plain>18. WangJ.QiuJ.TanW.ZhangY.WangH.ZhouX.LiuS.FengH.LiW.NiuX. Fisetin inhibits Listeria monocytogenes virulence by interfering with the oligomerization of listeriolysin O J. Infect. </plain></SENT>
<SENT sid="291" pm="."><plain>Dis. 2014 pii: jiu520  </plain></SENT>
</text></ref><ref id="B19-molecules-20-06533"><text><SENT sid="292" pm="."><plain>19. CascioferroS.TotsikaM.SchillaciD. Sortase A: An ideal target for anti-virulence drug development Microb. </plain></SENT>
<SENT sid="293" pm="."><plain>Pathog. 2014 77 105 112 10.1016/j.micpath.2014.10.007 <?supplied-pmid 25457798?>25457798 </plain></SENT>
</text></ref><ref id="B20-molecules-20-06533"><text><SENT sid="294" pm="."><plain>20. MaciaM.D.Rojo-MolineroE.OliverA. Antimicrobial susceptibility testing in biofilm-growing bacteria Clin. </plain></SENT>
<SENT sid="295" pm="."><plain>Microbiol. </plain></SENT>
<SENT sid="296" pm="."><plain>Infect. 2014 20 981 990 10.1111/1469-0691.12651 24766583 </plain></SENT>
</text></ref><ref id="B21-molecules-20-06533"><text><SENT sid="297" pm="."><plain>21. WangJ.ZhouX.LiuS.LiG.ZhangB.DengX.NiuX. Novel inhibitor discovery and the conformational analysis of inhibitors of listeriolysin O via protein-ligand modeling Sci. </plain></SENT>
<SENT sid="298" pm="."><plain>Rep. 2015 5 10.1038/srep08864 <?supplied-pmid 25820628?>25820628 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
